Oertel Michael, Eich Hans Theodor
Albert-Schweitzer-Campus 1, Gebäude A1, 48149 Münster, Deutschland Klinik für Strahlentherapie - Radioonkologie, Universitätsklinikum Münster.
Gynakologe. 2022;28(6):511-518. doi: 10.1007/s00761-022-01163-2. Epub 2022 Apr 25.
Lymphoma cells are highly radiosensitive and consequently, radiation therapy is a rational addition to systemic therapy in the treatment of leukemia. Especially as a conditioning regimen before allogeneic stem cell transplantation, radiation therapy, in the form of total body irradiation, is an established concept.
The present work provides an overview on the execution and side effects of radiation treatment in leukemia. Especially (long-term) side effects after total body irradiation are presented.
A selective search in the database PubMed on radiation treatment of leukemia and on total body irradiation has been carried out, focusing on toxicities as well as technical and conceptional innovations.
Total body irradiation is a successful conditioning therapy before allogeneic stem cell transplantation and is accompanied by a diverse, but manageable, toxicity spectrum with endocrinological, cardiopulmonary, ophthalmological, nephrological and neurological long-term side effects as well as secondary neoplasia. In addition, low-dose radiotherapy may be utilized to treat myeloid sarcoma (chloroma).
The variety of side effects after total body irradiation requires an interdisciplinary and long-term aftercare provided by radiation oncologists and medical oncologists/the transplantation team. Technical evolutions may result in a more selective targeting of the bone marrow and lymphatic organs. At the moment, these techniques are not established in clinical routine but are being evaluated in clinical trials.
淋巴瘤细胞对放疗高度敏感,因此放疗是白血病全身治疗的合理补充。特别是作为异基因干细胞移植前的预处理方案,全身照射形式的放疗是一个既定的概念。
本研究概述了白血病放疗的实施及副作用。特别介绍了全身照射后的(长期)副作用。
在PubMed数据库中对白血病放疗和全身照射进行了选择性检索,重点关注毒性以及技术和概念创新。
全身照射是异基因干细胞移植前一种成功的预处理疗法,伴有多种但可控的毒性反应,包括内分泌、心肺、眼科、肾脏和神经方面的长期副作用以及继发性肿瘤。此外,低剂量放疗可用于治疗髓系肉瘤(绿色瘤)。
全身照射后副作用多样,需要放疗肿瘤学家和医学肿瘤学家/移植团队提供跨学科的长期随访。技术进步可能会使对骨髓和淋巴器官的靶向更具选择性。目前,这些技术尚未在临床常规中应用,但正在临床试验中进行评估。